RxDoctor Payments DataLook up a doctor →

Samuel Miller, MD

Neurology · Baltimore, MDNPI 1851352942

Payments from drug & device makers

$179,362in general payments, 2019–2025

Across 851 payments — averaging $210.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$165K
  • Novartis$2K
  • Biogen$2K
  • Amgen$1K
  • Lilly USA, LLC$896
  • Teva Pharmaceuticals USA, Inc.$843
  • plus $8K from 42 others

What the payments were for

  • Consulting fees$2,7252%
  • Speaking & faculty fees$154,19686%
  • Travel & lodging$5,0523%
  • Food & beverage$17,10410%
  • Education$2840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$179,362 in reported general payments places this provider in the 90th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$229,018
Medicare patients
857
Services billed
1,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$265,230
MayzentSiponimod16$237,683
QuliptaAtogepant139$179,138
FingolimodFingolimod Hcl14$136,169
Kesimpta PenOfatumumab13$112,434
Avonex (4 Pack)Interferon Beta-1a13$108,003
AptiomEslicarbazepine Acetate20$89,180
Glatiramer Acetate26$70,776
Nurtec OdtRimegepant Sulfate20$42,879
UbrelvyUbrogepant26$35,880
Emgality PenGalcanezumab-Gnlm38$34,683
Aimovig AutoinjectorErenumab-Aooe33$32,553
Ajovy AutoinjectorFremanezumab-Vfrm16$23,560
NuedextaDextromethorphan Hbr/Quinidine12$19,520
NeuproRotigotine11$16,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$90$265,23015 claims
NovartisMayzent$1,853$237,68316 claims
AbbVieQulipta, Ubrelvy$164,801$215,018165 claims
BiogenAvonex (4 Pack)$1,825$108,00313 claims
Sunovion Pharmaceuticals Inc.Aptiom$577$89,18020 claims
PfizerNurtec Odt$43$42,87920 claims
UCB, Inc.Neupro, Vimpat$194$32,99823 claims
Avanir Pharmaceuticals, Inc.Nuedexta$114$19,52012 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$24$3,40815 claims
Upsher-smith Laboratories LLCTopiramate$111$1,22469 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 neurology providers in Maryland.

Other neurology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →